Results 181 to 190 of about 168,529 (313)

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang   +3 more
wiley   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen   +7 more
wiley   +1 more source

Hyper-response to cardiac resynchronization with permanent His bundle pacing: Is parahisian pacing sufficient?

open access: yesHeartRhythm Case Reports, 2015
Olujimi A. Ajijola, MD, PhD   +5 more
doaj   +1 more source

Cardiac arrhythmia, developmental delay, epilepsy and ichthyosis due to Xp22.31 deletion: review of literature and case report. [PDF]

open access: yesTransl Pediatr
Dantsev IS   +9 more
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher   +12 more
wiley   +1 more source

Arrhythmogenic right ventricular cardiomyopathy: Electroarchitecture of the substrate

open access: yesHeartRhythm Case Reports, 2016
Atsuyuki Watanabe, MD   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy